GC Biopharma's Hunterase Phase 3 Trial Shows Promising Results for Hunter Syndrome Patients GC Biopharma has reported significant Phase 3 clinical trial outcomes for Hunterase, an innovative treatment for Hunter Syndrome, published in a leading journal.

GC Biopharma's Hunterase Phase 3 Trial Shows Promising Results for Hunter Syndrome Patients #South_Korea #GC_Biopharma #Yongin #Hunterase #Hunter_Syndrome